Michael Ammar, MD
Retina Specialist · Poway, CANPI 1982099115
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Regeneron Healthcare Solutions, Inc. accounts for 66.1% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $29,961, more than ten times the $1,950 reported in 2019.
Across 193 payments — averaging $406.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$52K
- Genentech USA, Inc.$10K
- Regeneron$9K
- Apellis Pharmaceuticals, Inc.$2K
- Alcon$2K
- AbbVie$789
- plus $3K from 16 others
What the payments were for
- Consulting fees$15,34620%
- Speaking & faculty fees$44,01156%
- Travel & lodging$9,16312%
- Food & beverage$9,99213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 61 | $51,890 |
| Genentech USA, Inc. | 45 | $10,158 |
| Regeneron | 8 | $8,509 |
| Apellis Pharmaceuticals, Inc. | 10 | $2,368 |
| Alcon | 11 | $1,787 |
| AbbVie(2 entities) | 21 | $789 |
| Glaukos Corporation | 5 | $686 |
| Harrow Eye, LLC | 4 | $359 |
| Alimera Sciences, Inc. | 6 | $350 |
| Astellas Pharma US Inc | 7 | $256 |
| Lombart Brothers, Inc. | 1 | $239 |
| Notal Vision, Inc. | 1 | $228 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $226 |
| Biotissue Holdings Inc. | 2 | $153 |
| Ocular Therapeutix, Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 1 | $123 |
| Sight Sciences, Inc. | 1 | $86 |
| Mallinckrodt Hospital Products Inc. | 2 | $70 |
| Carl Zeiss Meditec USA, Inc. | 1 | $50 |
| Biogen | 1 | $20 |
| Sandoz | 1 | $20 |
| Neurotech Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$54,831
- VABYSMO$8,291
- EYLEA$4,947
- SUSVIMO$3,241
- Lucentis$2,265
- DAILIES$499
- Clareon$421
- Syfovre$404
- OZURDEX$370
- Tecnis IOL$350
- iStent inject Trabecular Micro-Bypass Stent System$255
- VUITY$250
- Iluvien$244
- OPD-III$239
- KXL System$181
- iDose TR$160
- Luxor$144
- DEXTENZA$125
- CATALYS SYSTEM$124
- enVista MX60 IOL$123
How this compares
$78,511 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 174 | $7,396 |
| Bromfenac Sodium | 16 | $4,670 |
| VyzultaLatanoprostene Bunod | 16 | $3,652 |
| MoxifloxacinMoxifloxacin Hcl | 68 | $1,206 |
| Ketorolac Tromethamine | 54 | $908 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 64 | $765 |
| Brimonidine Tartrate | 21 | $173 |
| Timolol Maleate | 13 | $123 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 14 | $121 |
| Latanoprost | 16 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta | $123 | $3,65216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 retina specialist providers in California.
Other retina specialist in Poway
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
- Diana DoStanford$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.